DE60217300D1 - Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression - Google Patents

Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Info

Publication number
DE60217300D1
DE60217300D1 DE60217300T DE60217300T DE60217300D1 DE 60217300 D1 DE60217300 D1 DE 60217300D1 DE 60217300 T DE60217300 T DE 60217300T DE 60217300 T DE60217300 T DE 60217300T DE 60217300 D1 DE60217300 D1 DE 60217300D1
Authority
DE
Germany
Prior art keywords
integrin expression
angionegesis
hemmer
infringement
investigating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217300T
Other languages
English (en)
Other versions
DE60217300T2 (de
Inventor
Naoto Ono
Senba
Naoko Hata
Yasuhiro Funahashi
Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE60217300D1 publication Critical patent/DE60217300D1/de
Publication of DE60217300T2 publication Critical patent/DE60217300T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60217300T 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression Expired - Lifetime DE60217300T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21
JP2001044646 2001-02-21
PCT/JP2002/001562 WO2002066073A1 (fr) 2001-02-21 2002-02-21 Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine

Publications (2)

Publication Number Publication Date
DE60217300D1 true DE60217300D1 (de) 2007-02-15
DE60217300T2 DE60217300T2 (de) 2007-10-04

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60229676T Expired - Lifetime DE60229676D1 (de) 2001-02-21 2002-02-21 Verfahren zur Untersuchung der Wirkung eines Angiogenese-Hemmers unter Vermittlung durch Hemmung der Integrin-Expression
DE60217300T Expired - Lifetime DE60217300T2 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60229676T Expired - Lifetime DE60229676D1 (de) 2001-02-21 2002-02-21 Verfahren zur Untersuchung der Wirkung eines Angiogenese-Hemmers unter Vermittlung durch Hemmung der Integrin-Expression

Country Status (12)

Country Link
US (1) US7122318B2 (de)
EP (2) EP1742052B1 (de)
JP (1) JP4255285B2 (de)
KR (1) KR20030080013A (de)
CN (2) CN100384482C (de)
AT (2) ATE412895T1 (de)
AU (1) AU2002233677B2 (de)
CA (1) CA2438427C (de)
DE (2) DE60229676D1 (de)
ES (2) ES2280502T3 (de)
HK (2) HK1059038A1 (de)
WO (1) WO2002066073A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438427C (en) 2001-02-21 2011-04-12 Eisai Co., Ltd. Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
US20040235866A1 (en) * 2001-09-05 2004-11-25 Takahisa Hanada Lymphocytic activation inhibitor and remedial agent for autoimmune disease
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2006090921A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物のリンパ球活性化抑制作用
RS52010B (en) 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
RU2128648C1 (ru) * 1993-09-10 1999-04-10 Эйсай Ко. Лтд. Производные сульфонамида, способы их получения, фармацевтическая композиция и способ лечения
ATE203515T1 (de) * 1996-03-29 2001-08-15 Searle & Co Meta-substituierte phenylsulphonamidderivate
AU738782B2 (en) * 1996-05-31 2001-09-27 Scripps Research Institute, The Methods and compositions useful for inhibition of alphavbeta5 mediated angiogenesis
JP2001524079A (ja) * 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
JP4039856B2 (ja) 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
CA2438427C (en) 2001-02-21 2011-04-12 Eisai Co., Ltd. Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Also Published As

Publication number Publication date
US7122318B2 (en) 2006-10-17
EP1362601A1 (de) 2003-11-19
DE60229676D1 (de) 2008-12-11
WO2002066073A1 (fr) 2002-08-29
HK1059038A1 (en) 2004-06-18
ES2317368T3 (es) 2009-04-16
AU2002233677B2 (en) 2005-01-06
CA2438427C (en) 2011-04-12
DE60217300T2 (de) 2007-10-04
EP1362601A4 (de) 2005-07-06
ES2280502T3 (es) 2007-09-16
ATE412895T1 (de) 2008-11-15
EP1742052B1 (de) 2008-10-29
CN101025419A (zh) 2007-08-29
EP1742052A1 (de) 2007-01-10
EP1362601B1 (de) 2007-01-03
KR20030080013A (ko) 2003-10-10
JPWO2002066073A1 (ja) 2004-06-17
EP1362601B8 (de) 2007-02-28
JP4255285B2 (ja) 2009-04-15
HK1099363A1 (en) 2007-08-10
CA2438427A1 (en) 2002-08-29
CN1620313A (zh) 2005-05-25
US20040132783A1 (en) 2004-07-08
CN100384482C (zh) 2008-04-30
ATE350660T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
DE60217300D1 (de) Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression
DE10343896A1 (de) Testgerät zur Untersuchung von Körperflüssigkeiten
ATE404890T1 (de) Verfahren und vorrichtung zur schnellen tomographischen messung der elektrischen leitfähigkeitsverteilung in einer probe
ATE462350T1 (de) Verfahren und gerät zur laufenden überwachung der konzentration eines analyten
WO2005091893A3 (en) System for high dynamic range analysis in flow cytometry
FI20000417A0 (fi) Ihmiseen liittyvä mittausarviointi
Plavcan Scaling relationships between craniofacial sexual dimorphism and body mass dimorphism in primates: implications for the fossil record
DE59608030D1 (de) Verfahren und vorrichtung zur überprüfung eines sensors
DE602004020327D1 (de) Verfahren zur Detektierung von Temperaturänderungen
NO954897L (no) Fremgangsmåte for å bestemme et individs inflammasjonsindeks fra hele blodfibrinogen og hematokrit eller hemoglobinmålinger
CN101512011A (zh) 在生物介质中测定酶活性的方法
BRPI0409092A (pt) métodos para medir densidade, para deformar uma imagem de um furo de sondagem, e para efetuar registro de densidade
McFarlane et al. Estimating striae of Retzius periodicity nondestructively using partial counts of perikymata
ATE313788T1 (de) Feuchtigkeitsfühler mit kapazitivem feuchte- messelement und verfahren zur erfassung der luftfeuchtigkeit
ATE335434T1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
Bechtold et al. Comparison of field methods and models to estimate mean crown diameter
DE60112949D1 (de) Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes
DE602004025676D1 (de) Verfahren zur untersuchung einer zelle
DE602004027399D1 (de) Verfahren und vorrichtung zum testen eines objekts mit ultraschall
DE60203524D1 (de) Verfahren zur messung des arteriolendrucks
DE602008006604D1 (de) Verfahren zur verarbeitung von spaltkammermesssignalen
DE60104327D1 (de) Verfahren und vorrichtung zur in-line-messung von laserpulsen und verfahren zur messung mittels photoakustischer spektroskopie
DE50009357D1 (de) Verfahren zur bestimmung der belastbarkeit eines menschen
ATE363229T1 (de) Gerät zur herzzeitvolumenbestimmung eines patienten
ATE205942T1 (de) Verfahren und vorrichtung zur messung der strahlungstiefe einer strahlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition